













VENABLE Fitzpatrick *Considering IPR2017-00826 and IPR2017-01008 as one IPR, and IPR2017-00827 and IPR2017-01009 as one IPF FWD = Final Written Decision

Unpatentable)

VENABLE | Fitzpatrick

(Unpatentable)



Technology: Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor alpha ($TNF\alpha$). $TNF\alpha$ is a cytokine cell signaling protein that is involved in the inflammatory response that occurs in autoimmune diseases.

	AbbVie v. Amgen 1:16-cv-00666 (D. Del.) Settled	AbbVie v. Boehringer Ingelheim 1:17-cv-01065 (D. Del.) Settled	<i>Amgen v. AbbVie</i> IPR2015-01514 Institution denied	<i>Amgen v. AbbVie</i> IPR2015-01517 Institution denied			Coherus v. AbbVie IPR2017-00822, IPR2017-00823 Institution denied	IPR2017-00822, IPR2017-00826 / II IPR2017-00823 01008	IPR2017-00822, IPR2017-00826 / IPR2017- IPR2017-00823 01008
8,663,945	x				l	9,085,619	9,085,619 x	9,085,619 x x	9,085,619 x x
8,911,964	x				l		Sandoz v. AbbVie	Sandoz V AbbVio	Sandoz v. AbbVia Sandoz v. AbbVie
8,916,157	x		x		l		IPR2017-01823	IPR2017-01823 IPR2017-019	IPR2017-01823 IPR2017-01987
8,916,158				x			Institution denied		Institution denied during request for rehearing
8,926,975		x				8,802,100	8,802,100 x	8,802,100 x	8,802,100 x
8,961,973	X					8,911,737	8,911,737	8,911,737 ×	8,911,737 ×
8,986,693	X					8,974,790	8,974,790	8,974,790	8,974,790
9,018,361 9,090,867		x					Sandoz v. AbbVie	Sandoz v AbbVie Sandoz v Abi	Sandoz v. AbbVie Sandoz v. AbbVie
9,096,666	x	x					IPR2017-02106 Settled after institution	IPR2017-02106 IPR2017-021	IPR2017-02106 IPR2017-02105
9,220,781	x	~							
9,255,143		x				9,067,992	9,067,992 x	9,067,992 x	9,067,992 ×
9,266,949		x			İ	9,090,689	9,090,689	9,090,689 ×	9,090,689 x
9,272,041	x	x			ĺ	9,114,166	9,114,166	9,114,166	9,114,166
9,359,434	х				l		Sandoz v. AbbVie		
9,365,645	х						IPR2017-01824 Institution denied: Request for rel	IPR2017-01824 Institution denied; Request for rehearing denied;	
9,546,212		x						Appeal No. 18-2142 settled	
	Coherus v. AbbVie IPR2016-00172 FWD: All claims unpatentable; Appeal No. 17-2304	Boehringer Ingelheim v. AbbVie IPR2016-00408, IPR2016-00409 FWD: All claims unpatentable: Appeal	Coherus v. AbbVie IPR2016-00188 FWD: All claims unpatentable; Appeal No. 17-2305	Coherus v. AbbVie IPR2016-00189 FWD: All claims unpatentable; Appeal No. 17-2306	l	9,512,216	9,512,216 x	9,512,216 x	9,512,216 x
							<i>Sandoz v. AbbVie</i> IPR2018-00156 Institution denied	IPR2018-00156 3:18-cv-1266	IPR2018-00156 3:18-cv-12668 (D.N.J.)
	Affirmed (U.S. as Intervenor, Coherus	Nos. 17-2362 and 17- 2363 Affirmed (U.S. as	Affirmed (U.S. as Intervenor, Coherus	Affirmed (U.S. as Intervenor, Coherus		9,187,559	9,187,559 x	9,187,559 x x	9,187,559 x x
		Intervenor, Boehringer	settled)	settled)		9,750,808	9,750,808	9,750,808 ×	9,750,808 x
		Ingelheim settled)				10,155,039	10,155,039	10,155,039	10,155,039
8,889,135	x	x				10,159,732	10,159,732	10,159,732	10,159,732
9,017,680			x			10,159,733			
9,073,987				x		10,207,000	10,207,000	10,207,000	10,207,000

VENABLE | Fitzpatrick